FormWeb • mycophenolate mofetil PO (Capsule)

IHS FormWeb

Approved Formulary

Search by class Show Therapeutic Classes

Staff Telephone Numbers

Webpage Links

Add Formweb to your mobile device

Android iOS

IHS FormWeb

Approved Formulary

REMS FDA Documents #1^FDA Documents #2

Search results for:

mycophenolate mofetil PO (Capsule)

mycophenolate mofetil PO (Capsule)

REMS FDA Documents #1
REMS FDA Documents #2

Brand names: Cellcept

Form	Strength
CAPSULE, ORAL	250 mg

Display Immunosuppressive Agents Class: 924400

Medication comments:

USP <800> Hazardous Drug Assessment of Risk (AOR)
Per policy, these drugs are exempt from USP <800> handling requirements under normal circumstances. The following outlines must be followed.
generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	Activities
mycophenolate mofetil (Cellcept) PO [UD ⇒ UD]	250 mg capsule	Stock @ IDBH? Y NIOSH Table 1^↑
Pharmacy: Receiving / Storage / Preparation Exposure Risk: minimal	• Handling/preparation PPE Requirements: do not handle while pregnant; single CX gloves
	• Receiving from Distributor: Standard
	• Pharmacy Storage Area: Carousel
	• Packaging/Reconstitution Location: n/a
	• Compounding (Non-Sterile/Sterile) Location: n/a
	• Omnicell Load: Yes
Transport	• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Administration Exposure Risk: low	• Handling/administration PPE Requirements: Single pair of CX approved gloves. Wash hands after handling
	• Storage of Finished dose in Nursing Area/Procedural Area: Omnicell
	• Signage on Patient Door Required: No
	• Manipulation of Dosage Form: Standard
	• Special Manipulation for Administration: do not open capsule, do not handle while pregnant
Disposal / Spills	• Disposal of Drug Waste: Full- blue bin Trace/packaging- trash
	• Disposol of Used PPE: trash bin (inside plastic bag)
	• Spill management: n/a
NIOSH Supplemental Information: BBW for embry of fetal toxicity,malignancies,and serious infections,increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; Special Warning: Tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or directcontact with skin or mucous membranse of the powder contained in capsules and oral suspension. If such contact occurs,wash thoroughly with soap and water, rinse eyes with plain water
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.

Last updated: Jun. 11, 2025

Hazard.Drug Handling(USP 800) USP<800> Hazardous Drug / Assessment of Risk
Black Box Warnings Embryofetal Toxicity, Malignancies, and Serious Infections

UpToDate Lexidrug

Pharmacy Contact Info:

Main Inpatient Pharmacy: ext 4599, 3503
Fax: 704-878-7283

Director of Pharmacy - Randi Raynor, PharmD: ext 4501
Clinical Coordinator - Laura Rollings, PharmD: ext 4597
Pharmacy Informaticist - Stephen Pringle, PharmD: ext 7645
Pharmacy Technician Supervisor - Amy Wingler, CPhT: ext 7385
Pharmacy Automation Coordinator (Omnicell) - Melissa Fulford, CPhT: ext 3556

This site is intended for the staff of Iredell Health System. While others may view accessible pages, Iredell Health System makes no warranty, express or implied, as to the use of this information outside of Iredell Health System. The content of this policy and procedure document serves as guidance to the delivery of quality patient care. Care providers are expected to exercise critical thinking and situational awareness skills, and in specific situations to take such action as is necessary for the delivery of quality patient care.